And Simon Kohl, founder and CEO of Latent Labs, knows this intimately. In a new episode of the pharmaphorum podcast, Kohl ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

In line with its deregulatory stance under new Commissioner Marty Makary, the US regulator has launched TEMPO – ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.

At this year's ASH congress, the results of the phase 1b/2 DURGA-1 of AZD0120 – a dual BCMA and CD19-directed CAR-T therapy – ...

Bayer has started a phase 3 trial of its intrauterine contraceptive Mirena in an endometrial condition that can lead to complications, including cancer, but has no approved therapies. The condition – ...

Eli Lilly's fast-growing blood cancer drug Jaypirca has bagged a new FDA approval as an earlier treatment for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma ...

The FDA has published new guidance aimed at reducing or stopping toxicity studies of monoclonal antibody-based drugs in non-human primates (NHPs), in the latest stage of an ongoing effort to reduce ...

The FDA has revealed the latest element in its adoption of AI, an agentic AI platform that agency staffers can use to streamline complex tasks. According to the US regulator, agentic AI – autonomous ...

In a boost for the UK life sciences sector, a new life sciences hub located at Barts Health NHS Trust in London has opened for business, with a planned investment of more than £800 million ($1.05 ...

American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides ...

Jointly Bayer and Orion Corporation-developed NUBEQA (Darolutamide) + Androgen Deprivation Therapy (ADT) in combination with docetaxel is to be the first prostate cancer treatment to be made available ...